Heron Therapeutics, Inc. (NASDAQ:HRTX) – Analysts at Oppenheimer Holdings dropped their FY2020 earnings per share estimates for Heron Therapeutics in a report released on Friday. Oppenheimer Holdings analyst D. Archila now anticipates that the biotechnology company will post earnings per share of $1.45 for the year, down from their prior estimate of $1.46. Oppenheimer Holdings currently has a “Buy” rating and a $27.00 target price on the stock. Oppenheimer Holdings also issued estimates for Heron Therapeutics’ FY2021 earnings at $3.29 EPS.
HRTX has been the subject of several other reports. Mizuho reissued a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a report on Tuesday, November 7th. Cantor Fitzgerald set a $31.00 price target on shares of Heron Therapeutics and gave the stock a “buy” rating in a report on Friday, October 20th. Cowen and Company reissued a “buy” rating and set a $40.00 price target on shares of Heron Therapeutics in a report on Monday, November 6th. BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Finally, Aegis reissued a “buy” rating and set a $33.00 price target on shares of Heron Therapeutics in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $28.36.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.10. The firm had revenue of $8.57 million during the quarter, compared to analysts’ expectations of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%.
A number of institutional investors and hedge funds have recently modified their holdings of HRTX. Janus Henderson Group PLC acquired a new position in Heron Therapeutics during the second quarter worth about $78,134,000. Vanguard Group Inc. grew its position in Heron Therapeutics by 40.2% during the first quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock worth $28,127,000 after buying an additional 537,563 shares during the period. State Street Corp grew its position in Heron Therapeutics by 30.7% during the first quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock worth $26,822,000 after buying an additional 420,113 shares during the period. Chartwell Investment Partners LLC acquired a new stake in shares of Heron Therapeutics in the third quarter valued at approximately $2,340,000. Finally, Credit Suisse AG grew its position in shares of Heron Therapeutics by 329.8% in the first quarter. Credit Suisse AG now owns 144,061 shares of the biotechnology company’s stock valued at $2,161,000 after purchasing an additional 110,539 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.